Monitor IGC's ability to make the first $197,708 payment on August 30, 2026. The conversion terms at 75% of the lowest trading price create substantial dilution risk if the company defaults, potentially leading to significant share price pressure. Watch for any signs of financial distress that could trigger conversion.
Price Chart
Executive Summary
IGC Pharma raised $526,000 through two bridge loans totaling $572,050 with significant dilution risk. The $353,050 loan from Vanquish Funding Group has a 12% interest rate, 7-month maturity, and allows conversion to equity at 75% of the lowest trading price over 10 days upon default, creating substantial downside risk for shareholders. A second $219,000 loan from One Deck Capital adds to the company's financial obligations.
Key Financial Metrics
Key Facts
- IGC Pharma raised $307,000 from Vanquish Funding Group through a $353,050 promissory note with $46,050 original issue discount
- The note has a 12% interest rate and matures on February 28, 2027, with mandatory monthly payments starting August 30, 2026
- Upon default, Vanquish can convert the note into shares at 75% of the lowest trading price over the 10 trading days prior to conversion
- IGC also secured $219,000 in financing from One Deck Capital with interest and scheduled repayments
- Proceeds from both loans will be used for general working capital purposes
Financial Impact
Raised $526,000 in cash through two bridge loans totaling $572,050 in obligations with significant dilution risk upon default
Risk Factors
- Significant dilution risk if the company defaults on the Vanquish loan, allowing conversion at 75% of the lowest trading price
- High debt burden with $572,050 in short-term obligations for a company with only $28M market cap
- Risk of default on the large $197,708 payment due August 30, 2026, which could trigger cross-default provisions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001185185-26-000846 |
| Document: igcex10-1.htm | 0001185185-26-000846 |
| Document: igc8k031126.htm | 0001185185-26-000846 |
| Document: igcex10-3.htm | 0001185185-26-000846 |
| Document: 0001185185-26-000846-index-headers.html | 0001185185-26-000846 |
| Document: 0001185185-26-000846-index.html | 0001185185-26-000846 |
| Document: 0001185185-26-000846.txt | 0001185185-26-000846 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | DEFA14A | $0.2434 | awaiting T+60 | — | $0.2500 (+2.71%) |
Oct 21, 2026 4d ago | DEF 14A | $0.2500 | awaiting T+60 | — | $0.2500 (0.00%) |
Jul 6, 2026 15w ago | 8-K | $0.2780 $0.2689 | ▼ −3.27% | ▼ −5.27% | $0.2500 (−10.07%) |
Jun 8, 2026 19w ago | 8-K | $0.2850 $0.2985 | ▲ +4.74% | ▼ −0.16% | $0.2500 (−12.28%) |
Apr 20, 2026 26w ago | 8-K | $0.3200 $0.2563 | ▲ +19.91% | ▲ +26.81% | $0.2500 (+21.88%) |
Mar 12, 2026 32w ago | 8-K | $0.2800 $0.2900 | ▼ −3.57% | ▲ +7.13% | $0.2500 (+10.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers